Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases

Sponsor
Assiut University
Study ID
NCT06983366
Status
Recruiting
Apply to this trial

Conditions

  • Bronchiectasis
  • COPD
  • ILD
  • Pleural Effusion Disorder
  • Pneumonia
  • Pneumothorax
  • Pulmonary Oedema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Lung Ultrasound — DIAGNOSTIC_TEST
    All enrolled patient will be subjected to Lung Ultrasound examination LUS

Study Details

This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.

Key Dates

First listed
May 21, 2025
Start date
May 30, 2025
Status verified
Apr 2026
Primary completion
Jul 1, 2026
Completion
Aug 1, 2026

Study Design

Enrollment
700 participants (estimated)

Arms

  • Arm: Chronic obstructive pulmonary disease (COPD)
    Chronic obstructive pulmonary disease patients will be further classified as mild, moderate, severe, and very severe according to GOLD classification.
  • Arm: Pneumothorax
    Patients with Pneumothorax
  • Arm: Community-acquired pneumonia (CAP)
    Community-acquired pneumonia will be classified using the CURB-65 score into mild, moderate, and severe.
  • Arm: Interstitial lung diseases (ILDs)
    Interstitial lung diseases will be further classified using FVC% classes, categorized as mild, moderate, and severe.
  • Arm: Bronchiectasis
    patients with non-cystic fibrosis bronchiectasis
  • Arm: Pleural Effusion
    Patients with pleural effusion
  • Arm: Pulmonary Oedema
    Patient with any degree of Pulmonary oedema
  • Arm: Control
    Healthy control subjects for comparison

Primary Outcome Measure

Discriminative performance of LSI (total score, 0-36) between disease groups [ Time Frame: At Baseline ]

Central Contacts

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies